- Specialization
Biotechnologyand 1 more specialization valuesLess
- Scientific Discovery
- Business
- Scientific Research
- Market
- Life Sciences
- Ecosystem
- Not applicable
- Customers
- Not classified
More details
- Organization type
- Commercial Company
- Ecosystem
- Not applicable
- Business
- Scientific Research
- Specialization
- Biotechnology, Scientific Discovery
- Market
- Life Sciences
- Customers
- Not classified
- Delivery models
- Not classified
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Pre Seed
- Reported funding amount
- Not classified
About
Eris Biotech is developing oral, first-in-class small-molecule cancer therapeutics that block tumor immune evasion and immune suppression. Its initial portfolio targets solid tumors, beginning with mesothelioma, and differentiates itself by reawakening the immune system rather than directly killing cancer cells, while avoiding protein targets and emphasizing oral administration and safety.
Market
Eris Biotech competes in oncology therapeutics, specifically tumor-selective hypoxia-activated prodrugs and cancer immunotherapy focused on immune-evasion mechanisms. Its differentiation is to activate drugs in low-oxygen solid-tumor environments and block tumor communication through immune-suppressing vesicles, aiming to restore immune surveillance while limiting systemic toxicity; the company also highlights oral administration and a non-protein-target mechanism. The closest named comparables in the available evidence are Merck KGaA's evofosfamide and Proacta's PR-104, while Codiak represents an adjacent extracellular-vesicle therapeutic approach rather than a like-for-like HAP competitor.
Eris Biotech targets oncology biopharmaceutical companies and clinical-development teams seeking safer treatments for solid tumors, initially mesothelioma. Its end-user ecosystem includes oncologists, cancer-care organizations, and patients who could benefit from orally administered, tumor-selective therapies with reduced systemic toxicity.
At a Glance
Problem
Eris Biotech is addressing one of cancer’s core defenses: immune evasion. The company says cancer’s ability to hide from the immune system is a major reason treatments fail, creating severe clinical pain in tumors that resist existing approaches. Its initial use case is mesothelioma, a rare cancer of the lung lining with a five-year survival rate below 13%, while its broader target is solid tumors. The available materials do not quantify the economic cost of treatment failure, market spending, or patient-care burden.
Product / Service
The company is developing cancer therapeutics based on small molecules that inhibit immune suppression and activate the body’s immune response against tumors. Eris says it has identified a pathway involved in immune evasion and developed a first-in-class small-molecule inhibitor, with the goal of enabling the immune system to attack tumors more aggressively.
The lead approach is described as an orally administered drug that does not depend on a protein target, which Eris says could make it suitable for a larger patient population. The therapeutic portfolio is intended to address multiple solid tumors, beginning with mesothelioma; public materials describe the assets as being in development rather than as an approved or marketed treatment.
Market
Eris competes in oncology and cancer drug discovery, specifically the emerging small-molecule immuno-oncology category focused on overcoming tumor-driven immune suppression. Its initial commercial and clinical beachhead is mesothelioma, with an eventual opportunity across solid tumors. The available research does not name specific direct competitors, so the relevant competitive set is the broader field of immunotherapies and experimental oncology therapeutics rather than a clearly identified peer group.
The company appears to be an early-stage, pre-commercial biotech: it was founded in 2023, participated in Y Combinator’s Winter 2024 batch, and is listed as having seed funding from Y Combinator. The sources do not report revenue, clinical-trial results, financing amounts, or an explicit pre-revenue designation, so traction is best characterized as program development and accelerator-backed formation rather than demonstrated commercial adoption.
Founders & Leadership
Funding History
Y Combinator
Recent News
The Y Combinator therapeutics directory listed Eris Biotech as raising a $10 million seed extension, with more than $2 million already wired.
BioSpace covered the financing pressures facing biotech founders and quoted Evita Weagel, CEO and cofounder of Eris Biotech, on the sector’s sensitivity to high interest rates.
The interview profiled Eris Biotech’s development of an oral small-molecule therapy intended to reawaken the immune system against cancer and identified Evita Weagel and Rachel as co-founders.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
As a seed-stage drug-discovery company, Eris currently appears to fund research and development through financing, including $500,000 raised, rather than a disclosed commercial pricing model. Its prospective revenue would come from commercializing or licensing oncology therapeutics; no active pricing, licensing, or recurring-revenue details are publicly stated in the available sources.